ANTIAGREGANTES PLAQUETARIOS

Jess Rolando De la Jara Cordero

ANTIAGREGANTES PLAQUETARIOS

Aspirina Tienopiridinas: Ticlopidina, Clopidogrel y Pasugrel Antagonistas de la GP IIB/IIIA: Abciximab, Tirofiban y Eptifibatide

Antiplatelet and anticoagulant agents Current Opinion in Cardiology, 2008

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

Ganongs Review of Medical Physiology 23 Ed, 2010

Acute Hyperglycemic crisis in the elderly, The Medical Clinics of North America, Jul 2004

Cieslas Hematology in Clinical Practice 4Ed, 2005

Hoffmans Hematology: Basic Principles and Practice

Mariebs Human Anatomy 6 Ed, 2010

Hoffmans Hematology: Basic Principles and Practice

Cieslas Hematology in Clinical Practice4Ed, 2005

Treatment of Von Willebrands Disease , The New England Journal of Medicine, 2004

Treatment of Von Willebrands Disease , The New England Journal of Medicine, 2004

Hoffmans Hematology: Basic Principles and Practice

ASPIRINA

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

Mayo Clinic Cardiology, 2007

Cardiag Drug Therapy 7 Ed, 2007

Cardiag Drug Therapy 7 Ed, 2007

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

, The Medical Clinics of North America, Jul 2004

CLOPIDOGREL

Cardiag Drug Therapy 7 Ed, 2007

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

Mayo Clinic Cardiology, 2007

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?, European Heart journal, 2012

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

PRASUGREL

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON-TIMI 38 Trial, New England Journal of Medicine, Nov 2007

TRITON/TIMI 38
El estudio TRITON TIMI-38 compar Prasugrel en dosis de 60 mg de carga y 10 mg de mantenimiento durante 15 meses con Clopidogrel 300 mg carga y 75 mg mantenimiento y demostr en 13608 pacientes con SICA STE (3354) o SICA STNE (10074) y derivados a ATC un a reduccin en el combinado de muerte, IAM no fatal y ACV de 9.9% vs 12.1% p<0.001

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

ticagrelor

The evolution of antiplatelet therapy in the treatment of Acute Coronary Syndromes, Drugs 2012

PLATO Trial, New England Journal of Medicine, Sep 2009

PLATO Trial, New England Journal of Medicine, Sep 2009

PLATO Trial, New England Journal of Medicine, Sep 2009

PLATO Trial, New England Journal of Medicine, Sep 2009

PLATO
En el estudio PLATelet inhibition and patient Outcomes (PLATO),
se aleatoriz a los pacientes con riesgo moderado-alto de SCASEST (programados para manejo conservador o invasivo) o con SICA STE programados para angioplastia primaria a recibir clopidogrel 75 mg diarios, con una dosis de carga de 300 mg, o una dosis de carga de ticagrelor de 180 mg seguida de 90 mg dos veces al da El tratamiento se prolong 12 meses, con una duracion minima

deseable de 6 meses y una duracion media de exposicion al farmaco

en estudio de 9 meses

PLATO
El objetivo primario de eficacia compuesto (muerte de causa vascular,IAM o
accidente cerebrovascular) se redujo del 11,7% en el grupo declopidogrel al 9,8% en el grupo de ticagrelor (HR = 0,84; IC95%, 0,77-0,92; p < 0,001) La incidencia de trombosis en el stent confirmada se redujo del 1,9 al 1,3%

(p < 0,01) y la mortalidad total, del 5,9 al 4,5% (p < 0,001). En conjunto.
No hubo diferencias significativas en las tasas de hemorragias mayores definidas en el estudio PLATO entre los grupos de clopidogrel y ticagrelor (el 11,2 frente al 11,6%; p = 0,43)

Inhibidores de la gpiib/iiia

ACCP Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9 Ed, Feb 2012

Cardiag Drug Therapy 7 Ed, 2007

Cardiag Drug Therapy 7 Ed, 2007

Cardiag Drug Therapy 7 Ed, 2007

Cardiag Drug Therapy 7 Ed, 2007

Mayo Clinic Cardiology, 2007

Mayo Clinic Cardiology, 2007

, The Medical Clinics of North America, Jul 2004

, The Medical Clinics of North America, Jul 2004

, The Medical Clinics of North America, Jul 2004

New look at antiplatelet gent-related peptic ulcer: An update of prevention and treatment , Journla of Gastroenterology and Hepatology, Apr 2012

New look at antiplatelet gent-related peptic ulcer: An update of prevention and treatment , Journla of Gastroenterology and Hepatology, Apr 2012

New look at antiplatelet gent-related peptic ulcer: An update of prevention and treatment , Journla of Gastroenterology and Hepatology, Apr 2012

New look at antiplatelet gent-related peptic ulcer: An update of prevention and treatment , Journla of Gastroenterology and Hepatology, Apr 2012

A patient-centered approach to exploring the Gastrointestinal issues of antiplatelet therapy, Mar 2012

Ticagrelor vs Clopidogrel in patients with Acute Coronary syndromes, New England journal of Medicine, Sep 2009

New Directions in Antiplatelet Therapy, Circulation Cardiovascular Interventions, Jun 2012